Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.

LIMA, Peru--(BUSINESS WIRE)--It is a great pleasure to announce that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has approved the daily oral use of ORLADEYO® (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older.

Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden, painful swelling of the skin, mucous membranes, and submucosal tissues. Until recently, treatment options for HAE were limited, which left patients facing a compromised quality of life and the constant risk of serious attacks.

“The approval of Orladeyo by DIGEMID is excellent news for the community of patients with hereditary angioedema in Peru,” commented Dr. Valnei Canutti, Scientific Director of Pint Pharma. “This innovative oral therapy represents a breakthrough for those living with this rare condition, offering an effective and convenient long-term prophylaxis option, preventing hereditary angioedema attacks.”

According to David Muñoz, CEO of Pint Pharma, “besides providing direct benefits to patients, the availability of Orladeyo in Peru highlights our continuous commitment to the advancement of research and innovation in the field of medical care for rare diseases.”

“The approval of Orladeyo is a great achievement for patients and proof of the successful collaboration among the medical community, regulators, and pharmaceutical companies in Peru to improve treatment options,” expressed Mauricio Botero, General Manager of Pint Pharma in the LATAM North Cluster.

About Orladeyo

ORLADEYO® (berotralstat), is the first and only oral therapy specifically designed to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older. One ORLADEYO capsule per day prevents HAE attacks by reducing plasma kallikrein activity. ORLADEYO is a product of BioCryst Pharmaceuticals, Inc., and its registration, marketing, and distribution are exclusively managed by Pint Pharma in Latin America.

About Pint Pharma

Pint Pharma, with headquarters in Vienna, Austria, is a pharmaceutical company specializing in purchasing or licensing and marketing pharmaceutical products for Latin America. We are a company focused on the community and we are proud to offer an exceptional experience and knowledge of the Latin American pharmaceutical industry, striving to offer the best treatment and service to the population through strategic alliances with our global business partners.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.